Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	LABEL_sum_dosing_errors int64	LABEL_dosing_error_rate float32	LABEL_wilson_label int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_count_Accidental overdose int64	METADATA_count_Drug administration error int64	METADATA_count_Intentional overdose int64	METADATA_count_Medication error int64	METADATA_count_Overdose int64	METADATA_wilson_lower_bound float32
[ 5 ]	308	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	To compare the safety and efficacy of 2 different bowel cleansing preparations prior to colonoscopy in adult subjects.	null	Colonoscopy	colonoscopy bowel preparation	null	2	arm 1: Active control arm 2: Investigational dose	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: multi dose formulation (tablet/solution) for oral administration prior to colonoscopy intervention 2: multi dose preparation (tablet/solution) for oral administration prior to colonoscopy	intervention 1: PEG electrolyte lavage solution + bisacodyl - reformulation intervention 2: PEG electrolyte lavage solution + bisacodyl	6	Anaheim \| California \| United States \| -117.9145 \| 33.83529 Orange \| California \| United States \| -117.85311 \| 33.78779 San Diego \| California \| United States \| -117.16472 \| 32.71571 New Smyrna Beach \| Florida \| United States \| -80.927 \| 29.02582 Laurel \| Maryland \| United States \| -76.84831 \| 39.09928 Franklin \| Tenne...	308	0	0	0	NCT00857272	1COMPLETED	2009-05-01	2009-02-01	Braintree Laboratories	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 4 ]	10	RANDOMIZED	SINGLE_GROUP	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of this research study is to see how certain hormones cause changes in mood and thinking in some depressed patients and to determine the effectiveness of mifepristone in treating some forms of depression. This study is conducted in conjunction with an observational study "Clinical and Biological Characteri...	Eligibility Procedures: Before entering the study and prior to any other procedures, you will be asked to read and sign this consent form. To determine if you are eligible for our study, you will then have a general medical (including menstrual cycle history on female patients) and psychiatric history taken, a physical...	Affective Disorders, Psychotic Depressive Disorder		null	2	arm 1: Receive mifepristone for 8 days arm 2: Receive placebo rather than mifepristone	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: Placebo medication	intervention 1: Mifepristone (RU-486) intervention 2: Placebo	1	Stanford \| California \| United States \| -122.16608 \| 37.42411	10	0	0	0	NCT00867360	6TERMINATED	2009-05-01	2005-08-01	Stanford University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2 ]	44	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	A study to test the pharmacokinetics after twice daily administration of MK-0941 or placebo in subjects with type 2 diabetes who have inadequate control on metformin.	null	Diabetes Mellitus, Type 2		null	2	arm 1: MK-0941 arm 2: Placebo Comparator	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): partic...	intervention 1: MK-0941 intervention 2: Comparator: Placebo	0	null	44	0	0	0	NCT00873821	1COMPLETED	2009-05-01	2008-12-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	2MALE	false	The investigators are hypothesizing that by offering both self-help materials and mailed nicotine lozenges we will be able to help increase tobacco abstinence rates among ST users, as well as decrease tobacco withdrawal.	Smokeless tobacco (ST) is a known human carcinogen. Long-term ST use is known to increase the risk for oropharyngeal cancer. Most smokeless tobacco users wish to quit. Assisted-self help interventions (i.e., self-help manual, a targeted video, and two support telephone phone calls) have been shown to be superior to man...	Smokeless Tobacco Use	tobacco chew nrt nicotine lozenges self-help	null	2	arm 1: Self-help counseling material and 4 mg nicotine lozenges arm 2: self help counseling material and placebo nicotine lozenges	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 4 mg nicotine lozenges, ad lib, for 12 weeks. intervention 2: Placebo nicotine lozenges	intervention 1: nicotine replacement therapy intervention 2: placebo NRT	2	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163 Eugene \| Oregon \| United States \| -123.08675 \| 44.05207	60	0	0	0	NCT00888459	1COMPLETED	2009-05-01	2008-04-01	Mayo Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	null	The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.	null	Allergic Conjunctivitis		null	2	arm 1: active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14). arm 2: Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 0.25% Ophthalmic Solution, one drop in each eye at each of two visits. intervention 2: Vehicle without active, one drop in each eye at each of two visits.	intervention 1: alcaftadine intervention 2: Placebo	2	Fairfield \| Ohio \| United States \| -84.5605 \| 39.34589 Mason \| Ohio \| United States \| -84.30994 \| 39.36006	60	0	0	0	NCT00889330	1COMPLETED	2009-05-01	2009-04-01	Vistakon Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	40	null	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to assess pharmacokinetic and pharmacodynamic characteristics of oral lenalidomide monotherapy administered to patients with Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS).	null	Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)		null	2	arm 1: Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or e...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Lenalidomide 5-mg capsules for oral administration intervention 2: Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.	intervention 1: Lenalidomide intervention 2: Recombinant human erythropoietin	1	Tampa \| Florida \| United States \| -82.45843 \| 27.94752	39	0	0	0	NCT00910858	1COMPLETED	2009-05-01	2005-01-01	Celgene Corporation	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	24	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Our hypothesis is that the medication approved for treatment of high blood cholesterol levels, Colesevelam HCl (WELCHOL), decreases colonic transit and permeability in patients with diarrhea due to irritable bowel syndrome. This effect is thought to result from the effect of the medication on bile acids, which can cau...	Background: Irritable bowel syndrome (IBS) affects about 15% of the U.S. population, about 5% having predominant diarrhea; current treatment is suboptimal as it may not be tolerated, lead to side effects or insufficient benefit. Bile acid malabsorption (BAM) is recognized as a cause of chronic diarrhea and has been in...	Irritable Bowel Syndrome Diarrhea	bile acid malabsorption permeability diarrhea IBS stool	null	2	arm 1: Participants received colesevelam 1.875 g twice daily arm 2: Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days intervention 2: Inert capsule matching the study drug, given twice daily	intervention 1: Colesevelam intervention 2: Placebo	1	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163	24	0	0	0	NCT00911612	1COMPLETED	2009-05-01	2009-01-01	Mayo Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	26	RANDOMIZED	SINGLE_GROUP	0TREATMENT	1SINGLE	true	1FEMALE	false	A study to compare the skin irritation potential of two marketed gels for acne treatment, each applied to half of the face of healthy volunteers.	At the Baseline Visit, following satisfaction of entry criteria and screening procedures, all subjects will be applying two products to their faces, each on one side only. The side of the face receiving each product is randomly assigned. One group will use Retin-A MICRO Gel, (tretinoin) 0.04% Pump on the left side of t...	Acne Vulgaris	acne irritation objective sensory methods	null	1	arm 1: Once daily use in a split face model: 1. Tretinoin gel 2. Adapalene Benzoyl peroxide	[ 0 ]	2	[ 0, 0 ]	intervention 1: Tretinoin gel 0.04% used once daily in a split-face model intervention 2: Adapalene .1% and Benzoyl peroxide 2.5%	intervention 1: Tretinoin gel intervention 2: Adapalene and Benzoyl peroxide	1	Broomall \| Pennsylvania \| United States \| -75.35658 \| 39.9815	26	0	0	0	NCT00919191	1COMPLETED	2009-05-01	2009-04-01	Bausch Health Americas, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	10	RANDOMIZED	CROSSOVER	0TREATMENT	3TRIPLE	false	0ALL	true	Involuntary oscillations of the eyes (nystagmus) impairs vision so that affected patients, who have neurological disorders such as Multiple Sclerosis (MS) , cannot read or watch TV. Two medicines have been reported to suppress nystagmus and improve vision in such patients: gabapentin and memantine. The investigators se...	The study entails careful measurements of visual acuity and precise measurements of eye movements, using a contact lens device (magnetic search coil method). In this way, it is possible to make objective and reliable measurements of the effect of each drug, which are unbiased by the investigator or the patient.	Nystagmus	gabapentin memantine nystagmus Drug treatment	null	2	arm 1: Increasing dose to 300 mg four times per day (total of 1200 mg/day) arm 2: Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: increasing to 1200 mg/day intervention 2: increasing to 40 mg/day	intervention 1: gabapentin intervention 2: memantine	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	20	0	0	0	NCT00928954	1COMPLETED	2009-05-01	2005-02-01	Case Western Reserve University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2 ]	62	RANDOMIZED	FACTORIAL	null	0NONE	true	0ALL	false	The purpose of this study was to examine the role skeletal muscle perfusion plays in mediating muscle protein synthesis in healthy older and younger individuals. The investigators hypothesized that normalization of muscle perfusion in older men and women via exercise or infusion of a vasodilator would enhance nutritive...	The purpose of this study was to examine muscle protein metabolism in healthy young and elderly subjects during pharmacologic vasodilation of the lower limb vasculature in combination with increased amino acids delivery. We obtained femoral arteriovenous blood samples and v. lateralis muscle biopsies during a primed co...	Aging	metabolism exercise sodium nitroprusside	null	5	arm 1: 45 minutes of treadmill walking at 40% VO2 peak arm 2: 45 minutes of treadmill walking at 40% VO2 peak arm 3: Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min arm 4: Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min arm 5:...	[ 1, 1, 1, 1, 1 ]	3	[ 10, 0, 7 ]	intervention 1: 45 minuties of treadmill walking was completed at 40% VO2 peak intervention 2: Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min intervention 3: 7.5 gram Amino Acid drink	intervention 1: Aerobic Exercise intervention 2: Sodium Nitroprusside intervention 3: Amino Acid Drink	0	null	62	0	0	0	NCT00945256	1COMPLETED	2009-05-01	2003-05-01	The University of Texas Medical Branch, Galveston	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	1	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to determine the safety and benefit of Thalidomide with primary sclerosing cholangitis (PSC). This is a six month study.	At entry, patients will have a complete history and physical, blood tests, ultrasound, and will complete questionnaires. Eligible patients will take Thalidomide 400 mg once a day in the evening. Patients will start a dose of 100 mg per day for two weeks, increasing by 100 mg per day every two weeks to a maximum dose of...	Primary Sclerosing Cholangitis	PSC Thalidomide	null	1	arm 1: Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.	[ 0 ]	1	[ 0 ]	intervention 1: Titrate to 400 mg daily for 6 months	intervention 1: Thalidomide	1	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163	1	0	0	0	NCT00953615	6TERMINATED	2009-05-01	2006-04-01	Mayo Clinic	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	30	RANDOMIZED	SINGLE_GROUP	1PREVENTION	1SINGLE	true	0ALL	false	This is a single-center study, randomized, Investigator/Evaluator-blinded bilateral (split-face) comparison. The objective: To assess the benefit of the concomitant use of a Moisturizing Lotion in reducing the skin irritation induced by a adapalen gel treatment in Chinese Subjects.	The interest \& relevance of the concomitant use of a non-comedogenic moisturizer in order to decrease retinoid irritation has already been demonstrated in Caucasian patients. Such interest of associating a moisturizer when Differin® gel is prescribed has not been demonstrated in Asian populations.	Healthy Skin		null	1	arm 1: None	[ 0 ]	2	[ 0, 10 ]	intervention 1: Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks. Visits will be conducted weekly for a maximum of 5 visits. intervention 2: Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks...	intervention 1: adapalen 0.1% intervention 2: Cetaphil®	1	Singapore \| N/A \| Singapore \| 103.85007 \| 1.28967	60	0	0	0	NCT00971282	1COMPLETED	2009-05-01	2008-12-01	Galderma R&D	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	22	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The objective of this study is to determine the time course of duloxetine efficacy on the symptoms of Major Depressive Disorder (MDD)and on the symptoms of Soft Tissue Discomfort Syndrome(STDS) via use of 24-hour Actigraph™ measures. We hypothesize that there will be a reduction in both MDD and STDS symptoms in MDD pa...	null	Major Depressive Disorder Soft Tissue Discomfort Syndrome Pain		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: 30-60 mg daily for 8 weeks	intervention 1: Duloxetine	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	0	0	0	0	NCT01035073	1COMPLETED	2009-05-01	2006-04-01	University of Pennsylvania	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	208	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation	null	Growth Disorders Intrauterine Growth Retardation	Short height intra-uterine growth retardation Genotonorm continuous treatment intermittent treatment	null	3	arm 1: Continuous 0.7 IU/kg/week or 0.03 mg/kg/day arm 2: Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day arm 3: Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day	[ 1, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: 0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection intervention 2: 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection intervention 3: 1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)	intervention 1: Genotonorm intervention 2: Genotonorm intervention 3: Genotonorm	31	Angers \| France \| France \| -0.55202 \| 47.47156 Grenoble \| France \| France \| 5.71479 \| 45.17869 Paris \| France \| France \| 2.3488 \| 48.85341 Amiens \| N/A \| France \| 2.3 \| 49.9 Besançon \| N/A \| France \| 6.01815 \| 47.24878 Bordeaux \| N/A \| France \| -0.5805 \| 44.84044 Bordeaux \| N/A \| France \| -0.5805 \| 44.84044 Boulogne \| ...	206	0	0	0	NCT01073605	1COMPLETED	2009-05-01	1993-07-01	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	24	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	2MALE	false	This study will determine if MK-3614, given as single doses, is safe and well tolerated in healthy males and male participants with mild to moderate hypertension.	Up to three planned panels of either 8 healthy participants (Panels A and B) or 8 participants with mild to moderate hypertension (Panel C) will be enrolled. In Panels A and B, 8 participants will alternately receive single rising doses of MK-3614 or placebo. All doses will be administered in the fasted state, except P...	Hypertension		null	3	arm 1: Healthy participants receive single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast except for Period 3. Period 3 dose was administered after the ingestion of a hi...	[ 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: MK-3614 intervention 2: Comparator: Placebo	0	null	78	0	0	0	NCT01104545	1COMPLETED	2009-05-01	2008-11-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	288	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	true	This was a multicenter, open-label extension study for subjects completing either of 2 pivotal efficacy studies (NCT00401193 or NCT00386308). The study consisted of a treatment phase of 9 menstrual periods to assess the safety of tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (ma...	null	Menorrhagia	Menorrhagia Heavy Menstrual Bleeding Lysteda	null	1	arm 1: Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).	[ 0 ]	1	[ 0 ]	intervention 1: Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.	intervention 1: Tranexamic acid	92	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Tucson \| Arizona \| United State...	260	0	0	0	NCT01280981	1COMPLETED	2009-05-01	2007-04-01	Ferring Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	30	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	2MALE	false	The purpose of this study is to investigate how the body processes prasugrel and how prasugrel affects blood clotting in healthy Korean men. Three different dosing regimens of prasugrel will be given. Information on side effects will also be collected.	null	Healthy Volunteers		null	3	arm 1: Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days arm 2: Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days arm 3: Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: Tablets orally	intervention 1: Prasugrel	1	Seoul \| N/A \| South Korea \| 126.9784 \| 37.566	30	0	0	0	NCT01591317	1COMPLETED	2009-05-01	2009-03-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	59	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This is an expanded access programme to make Pegasys (peginterferon alfa-2a) available to patients with HBeAg-negative chronic hepatitis B in Morocco. Patients will receive Pegasys 180 mcg subcutaneously weekly for 48 weeks and efficacy and safety will be recorded during treatment and for 24 weeks of follow-up.	null	Hepatitis B, Chronic		null	1	arm 1: Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: 180 mcg subcutaneously weekly, 48 weeks	intervention 1: Peginterferon alfa-2a [Pegasys]	4	Casablanca \| N/A \| Morocco \| -7.61138 \| 33.58831 Casablanca \| N/A \| Morocco \| -7.61138 \| 33.58831 Rabat \| N/A \| Morocco \| -6.83255 \| 34.01325 Rabat \| N/A \| Morocco \| -6.83255 \| 34.01325	59	0	0	0	NCT01787279	1COMPLETED	2009-05-01	2006-01-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	164	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Smoking-related cardiopulmonary diseases account for a large number of hospital admissions. We investigated the efficacy of hypnotherapy as an aid to a counseling-based smoking cessation program in improving quit rates of hospitalized smoking patients at 12 and 26 weeks after hospital discharge. We compared outcomes wi...	Hospitalized patients with a cardiopulmonary diagnosis who were contemplating quitting were recruited into 4 groups: Hypnotherapy, Nicotine replacement therapy (NRT), both hypnotherapy and NRT, and self-quit group. All patients received self-help brochures and in-hospital counseling. Intervention groups received more e...	Smoking Cessation	Smoking cessation Tobacco abstinence hypnotherapy Nicotine replacement therapy	null	4	arm 1: Patients admitted with a cardiopulmonary illness received a 90 minute free hypnotherapy session within 2 weeks of discharge, and a standardized tape for smoking cessation and relaxation for continued use after the session. They also received self-help brochures, and counseling during hospitalization and by telep...	[ 0, 0, 0, 4 ]	2	[ 5, 0 ]	intervention 1: One 90 minute session within 2 weeks of hospital discharge intervention 2: free one month supply after hospital discharge	intervention 1: hypnotherapy intervention 2: Nicotine	1	Salem \| Massachusetts \| United States \| -70.89552 \| 42.51977	155	0	0	0	NCT01791803	1COMPLETED	2009-05-01	2006-01-01	North Shore Medical Center	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2 ]	44	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.	null	Type 2 Diabetes		null	4	arm 1: ITCA 650 (exenatide in DUROS) arm 2: ITCA 650 (exenatide in DUROS) arm 3: ITCA 650 (exenatide in DUROS) arm 4: ITCA 650 (exenatide in DUROS)	[ 0, 0, 0, 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: ITCA 650 (exenatide in DUROS)	3	Miami Gardens \| Florida \| United States \| -80.2456 \| 25.94204 Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711 San Antonio \| Texas \| United States \| -98.49363 \| 29.42412	44	0	0	0	NCT01798264	1COMPLETED	2009-05-01	2009-02-01	Intarcia Therapeutics	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 0 ]	79	RANDOMIZED	PARALLEL	1PREVENTION	0NONE	false	0ALL	true	The study hypothesis is that nutritional supplementation together with bisphosphonates have a better preserving effect on bone mineral density (BMD) after hip fracture than bisphosphonates alone and that nutritional supplementation given postoperatively for 6 months preserve lean body mass in elderly hip fracture patie...	Inclusion criteria: Men and women, ≥ 60 years of age with a recent fracture of the femoral neck or trochanter, admitted to any of the four University hospitals in Stockholm, Sweden. Patients are randomized into three groups by sealed enveloped technique in blocks by 12, thus assuring that each center had an equal distr...	Hip Fracture	Hip fracture Nutritional supplement Bisphosphonates Bone mineral density Body composition	null	3	arm 1: 35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group) arm 2: Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and...	[ 1, 1, 1 ]	3	[ 0, 10, 7 ]	intervention 1: The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months. intervention 2: The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12...	intervention 1: Risedronate intervention 2: Nutritional supplement intervention 3: Calcium and vitamin D3	1	Stockholm \| N/A \| Sweden \| 18.06871 \| 59.32938	79	0	0	0	NCT01950169	1COMPLETED	2009-05-01	2004-12-01	Karolinska Institutet	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	1	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to see if patients with chronic kidney disease have endothelial cells that don't function properly, which is thought to be a marker for cardiovascular risk. Endothelial cells line the heart and blood vessels. The investigators will treat your high cholesterol with a cholesterol-lowering dru...	null	Chronic Kidney Disease High Cholesterol	Chronic kidney disease High cholesterol	null	1	arm 1: Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood ...	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: Atorvastatin	0	null	0	0	0	0	NCT02133534	6TERMINATED	2009-05-01	2008-02-01	Duke University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 2 ]	22	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	true	2MALE	false	To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide 25 mg (Madopar HBS).	Single centre, double-blind, randomized, placebo-controlled, crossover study with four consecutive single-dose treatment periods. The washout period between doses was to be at least10 days. On each treatment period (25, 50 and 100 mg BIA 9-1067 or placebo), after completion of pre-dose assessments, BIA 9-1067-Placebo w...	Parkinson's Disease (PD)	Parkinson's disease (PD) Opicapone BIA 9-1067	null	4	arm 1: Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.) arm 2: Period 1: BIA 9-1067 50 ...	[ 0, 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: OPC, Opicapone intervention 2: PLC, Placebo intervention 3: controlled-release levodopa 100 mg/benserazide 25 mg	intervention 1: BIA 9-1067 intervention 2: Placebo intervention 3: Madopar® HBS	1	S. Mamede Do Coronado \| Trofa \| Portugal \| N/A \| N/A	86	0	0	0	NCT02169466	1COMPLETED	2009-05-01	2009-01-01	Bial - Portela C S.A.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	30	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	true	0ALL	null	To determine the relative bioavailability of 150 mg of dabigatran etexilate as pellets on food and of 150 mg of dabigatran etexilate as powder resolved in reconstitution solution, both with 150 mg of dabigatran etexilate as capsule in healthy volunteers	null	Healthy		null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None	intervention 1: Dabigatran etexilate pellets intervention 2: Dabigatran etexilate powder intervention 3: Dabigatran etexilate capsule	0	null	90	0	0	0	NCT02171611	1COMPLETED	2009-05-01	2009-03-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Current opinion regarding the use of steroids in the treatment of chronic subdural hematomas are mostly based on observational studies. Here we present data from a prospective randomized pilot study of twenty chronic subdural hematoma (CSDH) patients treated with dexamethasone or placebo for 30 days. Twenty patients w...	Patients Recruitment for this single-center double-blind randomized placebo-controlled study was performed between January 2007 and May 2009. Patients were enrolled based on the following inclusion criteria: 18 years and older with evidence of subacute or chronic supratentorial subdural hematoma by CT (computerized tom...	Hematoma, Subdural, Chronic	[C10.228.140.300.535.450.400.120]	null	2	arm 1: Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs). arm 2: Identical oral capsules filled with ...	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs). intervention 2: Identical oral capsules filled with lactose were admini...	intervention 1: Dexamethasone intervention 2: Placebo	0	null	20	0	0	0	NCT02362321	6TERMINATED	2009-05-01	2007-01-01	CHU de Quebec-Universite Laval	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	12	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.	null	Hepatitis D, Chronic		null	2	arm 1: Participants will receive peginterferon alfa-2a alone, administered over 48 weeks. arm 2: Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection. intervention 2: Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.	intervention 1: Peginterferon alfa-2a intervention 2: Ribavirin	1	Cagliari \| N/A \| Italy \| 9.11917 \| 39.23054	12	0	0	0	NCT02731131	1COMPLETED	2009-05-01	2004-09-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	14	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN). GSK1363089 is a new chemical entity that inhibits multiple receptor tyrosine kinases (RTKs) with growth-promoting and...	null	Neoplasms, Head and Neck	VEGFR2 XL880 foretinib Squamous Cell Cancer of the Head and Neck MET GSK1363089	null	1	arm 1: Participants who qualified for study entry received 240 mg of GSK1363089 (foretinib) on a 5-day on 9-day off schedule every 2 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: Multitargeted tyrosine kinase inhibitor	intervention 1: GSK1363089 (foretinib)	11	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727 Lebanon \| New Hampshire...	14	0	0	0	NCT00725764	1COMPLETED	2009-05-02	2007-08-27	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	140	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The current trial was designed to demonstrate faster recovery from a neuromuscular blockade (NMB) induced by rocuronium after reversal at 1-2 Post Tetanic Count (PTC) by 4.0 mg.kg-1 sugammadex compared to 50 µg.kg-1 neostigmine at reappearance of second twitch (T2) in participants undergoing laparoscopic cholecystectom...	In those surgical procedures where a neuromuscular block is desired for intubation and/or avoid unwanted muscular activity, anesthesiologists may use a more profound NMB until the end of surgery, e.g. in open abdominal procedures or during laparoscopic procedures in order to improve surgical conditions. Reversal with s...	Anesthesia, General		null	2	arm 1: 4.0 mg.kg-1 sugammadex at 1-2 PTC arm 2: 50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given. intervention 2: After the last dose of rocuronium has been administered, participants will receive, according to the randomization, ...	intervention 1: Rocuronium intervention 2: Sugammadex intervention 3: Neostigmine intervention 4: Atropine	0	null	133	0	0	0	NCT00724932	1COMPLETED	2009-05-03	2008-07-16	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	2,080	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the Respimat® in patients with COPD. Additional objectives include comparing the effects on dyspnea and...	null	Pulmonary Disease, Chronic Obstructive		null	5	arm 1: Matching Placebo arm 2: Low dose arm 3: Medium dose arm 4: High dose arm 5: Tiotropium Bromide	[ 2, 0, 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: Solution intervention 2: Solution intervention 3: Solution	intervention 1: BEA 2180 BR intervention 2: Tiotropium Bromide intervention 3: Placebo	178	Jasper \| Alabama \| United States \| -87.27751 \| 33.83122 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Berkeley \| California \| United States \| -122.27275 \| 37.87159 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Lakewood \| California \| United States \| -118.13396 \| 33.85363 Riverside \| California ...	2,080	0	0	0	NCT00528996	1COMPLETED	2009-05-05	2007-09-06	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	1	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine the safety and toxicity and feasibility of double umbilical cord blood transplantation (DUCBT) in patients with selected malignant and non-malignant, and to quantify the percentage and donor sources of mixed donor chimerism following DUCBT in patients with selected malignant an...	Allogeneic stem cell transplantation from an human leukocyte antigen (HLA) matched related family donor is the treatment of choice for a wide variety of malignant and non-malignant disorders. Unfortunately, only 25% of potential recipients have an HLA matched related family donor, leaving approximately 75% of potential...	Leukemia Lymphoma Neuroblastoma Immunodeficiencies Anemia	Cord Blood Transplant Allogeneic Stem Cell Transplant	null	6	arm 1: Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and...	[ 0, 0, 0, 0, 0, 0 ]	10	[ 0, 4, 0, 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours. intervention 2: None intervention 3: Melphalan 45mg/m2 (1.5 mg/kg IV for children \<1 year of age or \<10 kg) diluted in 0.9% NS ...	intervention 1: Alemtuzumab intervention 2: Total Body Irradiation intervention 3: Melphalan intervention 4: Busulfan intervention 5: Phenytoin intervention 6: Fludarabine intervention 7: Cyclophosphamide intervention 8: Horse Antithymocyte Globulin intervention 9: Rabbit Antithymocyte Globulin intervention 10: Thiotep...	1	New York \| New York \| United States \| -74.00597 \| 40.71427	1	0	0	0	NCT00801931	6TERMINATED	2009-05-05	2007-09-06	Columbia University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	1,050	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This is an open-label, multiple-dose, safety study of DIC075V in patients with acute post-operative pain following abdominal or orthopedic surgery.	This is an open-label, multiple-dose, multiple-day, single-arm safety study of repeat-doses of DIC075V in patients with acute post-operative pain following abdominal (i.e., non-laparoscopic abdominal surgeries) or orthopedic (e.g., hip or knee joint replacement) surgery. Eligible patients will receive DIC075V IV bolus ...	Pain, Postoperative	safety diclofenac pain, postoperative	null	1	arm 1: IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days	[ 0 ]	1	[ 0 ]	intervention 1: multiple doses up to 5 days	intervention 1: DIC075V (intravenous diclofenac sodium)	46	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Florence \| Alabama \| United States \| -87.67725 \| 34.79981 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Montgomery \| Alabama \| United States \| -86.29997 \| 32.36681 Montgomery \| Alabama \| Uni...	971	0	0	0	NCT00726388	1COMPLETED	2009-05-08	2008-09-15	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	204	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.	Prior to the implementation of Amendment 1/UK3 the study consisted of 3 phases - pre-randomization up to 35 days, up to 84 days placebo-controlled treatment and a 28-day observational follow up. After the implementation of Amendment 1/UK3, the study consisted of 4 phases - pre-randomization up to 35 days, up to 84 days...	Psoriatic Arthritis	psoriatic arthritis ACR PASI DAS pharmacokinetic biopsy	null	3	arm 1: Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD du...	[ 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: Capsules for oral administration intervention 2: Capsules for oral administration	intervention 1: Apremilast intervention 2: Placebo	38	Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Diepenbeek \| N/A \| Belgium \| 5.41875 \| 50.90769 Leuven \| N/A \| Belgium \| 4.70093 \| 50.87959 Merksem \| N/A \| Belgium \| 4.44903 \| 51.24623 Vancouver \| British Columbia \| Canada \| -123.11934 \| 49.24966 Victoria \| British Columbia \| Canada \| -123.35155 \| 48.4359 St. John's \| Ne...	380	0	0	0	NCT00456092	1COMPLETED	2009-05-09	2007-03-05	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	60	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	0ALL	false	The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis	null	Allergic Conjunctivitis		null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 0, 0, 0, 2 ]	2	[ 0, 10 ]	intervention 1: Ophthalmic Solution intervention 2: Ophthalmic Solution	intervention 1: Lifitegrast intervention 2: Placebo	1	Andover \| Massachusetts \| United States \| -71.137 \| 42.65843	60	0	0	0	NCT00882687	1COMPLETED	2009-05-10	2009-04-24	Shire	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	234	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety Follow-up. Patients randomized to romiplostim must complete the taper or discontinuation of medi...	null	Idiopathic Thrombocytopenic Purpura Thrombocytopenia Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Thrombocytopenic Purpura	splenectomy platelet AMG 531 thrombopoietin blood disorder bleeding disorder immune thrombocytopenic purpura idiopathic thrombocytopenic purpura immune (idiopathic) thrombocytopenic purpura TPO thrombopoietic protein	null	2	arm 1: Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10\^9/L for up to 52 weeks. arm 2: Medical standard of care treatments were selected and prescribed by the investigator according ...	[ 0, 5 ]	2	[ 0, 2 ]	intervention 1: None intervention 2: None	intervention 1: Medical Standard of Care for ITP intervention 2: Romiplostim	0	null	229	0	0	0	NCT00415532	1COMPLETED	2009-05-11	2006-12-01	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	64	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	This is a study to determine the safety and tolerability of 28 days of daily dosing of two doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and chronic infection due to Pseudomonas infection.	Bronchiectasis is a chronic disorder of the major bronchi and bronchioles characterized by permanent dilation, microbial infection, a persistent inflammatory response with the release of immune mediators and microbial toxins leading to destruction. The origin of bronchiectasis varies, but the presence of microbial infe...	Bronchiectasis	Bronchiectasis Respiratory Infections Amikacin Respiratory Tract Diseases Respiratory Tract Infections Lung Diseases Pseudomonas aeruginosa Amikacin liposome inhalation suspension (ALIS)	null	4	arm 1: Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™ arm 2: Subjects in this arm of the cohort 1 will receive matching placebo. arm 3: Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™ arm 4: Subjects in this arm of the cohort 2 will receive matching placebo	[ 0, 2, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer. intervention 2: Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer. intervention 3: Study subjects will receive Arikace™ 560 m...	intervention 1: 280 mg Arikayce™ intervention 2: Matching Placebo for Cohort 1 intervention 3: 560 mg Arikayce™ intervention 4: Matching Placebo for Cohort 2	18	Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Sofia \| N/A \| Bulgaria \| 23.32415 \| 42.69751 Athens \| N/A \| Greece \| 23.72784 \| 37.98376 Mosdós \| N/A \| Hungary \| 17.98853 \| 46.35379 Bangalore \| N/A \| India \| 77.59369 \| 12.9...	62	0	0	0	NCT00775138	1COMPLETED	2009-05-11	2008-06-24	Insmed Incorporated	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	3,834	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug give...	null	Heart Failure		null	2	arm 1: 50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years) arm 2: Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 50-mg losartan oral tablet intervention 2: 100-mg losartan oral tablet + 50-mg losartan oral tablet	intervention 1: Losartan 50 mg intervention 2: Losartan 150 mg	0	null	3,834	39	0.010172	1	NCT00090259	1COMPLETED	2009-05-13	2001-12-19	Organon and Co	4INDUSTRY	false	false	false	null	8	0	0	0	31	0.00745
[ 2 ]	18	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.	null	Type 2 Diabetes Mellitus		null	4	arm 1: None arm 2: None arm 3: Co-administration of sitagliptin and metformin arm 4: Co-administration of placebo to sitagliptin and placebo to metformin	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods. intervention 2: Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washou...	intervention 1: sitagliptin phosphate intervention 2: metformin hydrochloride intervention 3: Comparator: placebo sitagliptin intervention 4: Comparator: placebo metformin	0	null	72	0	0	0	NCT00830076	1COMPLETED	2009-05-14	2008-12-02	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	682	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	false	The objective of the trial is to assess the non-immunogenicity and safety of corifollitropin alfa (also known as Org 36286, SCH 900962 and MK-8962) in participants undergoing repeated COS cycles using a multiple dose GnRH antagonist protocol.	This trial is designed as an open-label, uncontrolled, repeated cycle trial to assess the non-immunogenicity and safety of corifollitropin alfa in participants undergoing repeated COS cycles for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) using a multiple dose GnRH antagonist protocol. The t...	In Vitro Fertilization	Infertility Pharmacological effects of drugs Hormones, Hormone Substitutes and Hormone Antagonists Pharmacological Actions Multi-center	null	1	arm 1: Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and contin...	[ 0 ]	5	[ 0, 2, 2, 2, 0 ]	intervention 1: Corifollitropin alfa 150 µg administered as a single subcutaneous dose. intervention 2: FSH administerd subcutaneously at a dose not to exceed 225 IU/day. intervention 3: GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day. intervention 4: (rec)hCG administered subcutaneously at a dose ...	intervention 1: Corifollitropin alfa intervention 2: FSH intervention 3: GnRH antagonist intervention 4: (rec)hCG intervention 5: Progesterone	0	null	682	0	0	0	NCT00696878	1COMPLETED	2009-05-15	2006-09-26	Organon and Co	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	356	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	To evaluate the effect of rufinamide on total partial seizure frequency in adolescent and adult participants (12 to 80 years, inclusive) with refractory partial onset seizures maintained on a maximum of 3 stable antiepileptic drugs (AEDs).	null	Epilepsy		null	2	arm 1: For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tab...	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: For the 12-day Titration Phase, one matching placebo tablet will be administered twice daily and increased by 1 matching placebo tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance pha...	intervention 1: Placebo intervention 2: Rufinamide	77	Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Northport \| Alabama \| United States \| -87.57723 \| 33.22901 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Little Rock \| Arkansas \| United ...	356	0	0	0	NCT00334958	1COMPLETED	2009-05-20	2006-02-13	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	660	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.	null	Migraine		null	3	arm 1: Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks arm 2: Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks arm 3: Participants receive one 140 mg telcagepant placebo and one...	[ 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None intervention 4: None	intervention 1: Telcagepant 140 mg intervention 2: Telcagepant 280 mg intervention 3: 140 mg telcagepant placebo intervention 4: 280 mg telcagepant placebo	0	null	656	0	0	0	NCT00797667	6TERMINATED	2009-05-20	2008-11-12	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	19	RANDOMIZED	CROSSOVER	2DIAGNOSTIC	2DOUBLE	false	0ALL	false	This study will investigate whether changes in inflammatory mediators produced by the nose after exposure to an allergen can be used to evaluate the anti-inflammatory effects of novel drugs for the treatment of allergic asthma.	null	Allergic Rhinitis		null	3	arm 1: placebo arm 2: 10 mg prednisone arm 3: 25 mg prednisone	[ 2, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks intervention 2: Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks. intervent...	intervention 1: Placebo intervention 2: prednisone intervention 3: prednisone	0	null	57	0	0	0	NCT00828061	1COMPLETED	2009-05-21	2009-02-04	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	681	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	0ALL	true	The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.	Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and effic...	Cytomegalovirus Infections	prevention prophylaxis Cytomegalovirus CMV allogeneic stem cell transplant SCT	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: 100 mg twice daily for up to 12 weeks intervention 2: twice daily for up to 12 weeks	intervention 1: maribavir intervention 2: placebo	97	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Duarte \| California \| United States \| -117.97729 \| 34.13945 La Jolla \| California \| United States \| -117.2742 \| 32.84727 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Francis...	674	0	0	0	NCT00411645	1COMPLETED	2009-05-23	2006-12-13	Shire	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	66	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to evaluate the efficacy, safety and tolerability of long-term use (up to 18 weeks) of valsartan in children 6 months to 5 years old with hypertension.	null	Hypertension	Children pediatrics High Blood Pressure Hypertension Valsartan	null	1	arm 1: Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: Extemporaneous suspension of valsartan, orally.	intervention 1: Valsartan	36	Hackensack \| New Jersey \| United States \| -74.04347 \| 40.88593 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Norfolk \| Virginia \| United States \| -76.28522 \| 36.84681 Antwerp \| N/A \| Belgium \| 4.40026 \| 51.22047 Edegem \| N/A \| Belgium \| 4.44504 \| 51.15662 Ghent \| N/A \| Belgium \| 3.71667 \| 51.05 Lak...	66	0	0	0	NCT00457626	1COMPLETED	2009-05-25	2007-04-09	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	72	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.	This is a double-blind, placebo-controlled, parallel group study in pediatric subjects who have persistent attention impairment following treatment for cancer. This trial has three phases: (1) pre-randomization to establish eligibility, (2) a 12-week, double-blind, placebo-controlled, parallel-group phase with dose esc...	Attention Impairment	Attention cancer chemotherapy donepezil acetylcholinesterase inhibitor	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on ...	intervention 1: Donepezil hydrochloride intervention 2: Placebo	31	Stanford \| California \| United States \| -122.16608 \| 37.42411 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 St Louis \| Missouri \| United States \| -90.19789 \| 38.62727 New Brunswick \| New Jersey \| United States \| -74.45182 \| 40.48622 Brooklyn \| New ...	130	0	0	0	NCT00688376	1COMPLETED	2009-05-26	2008-07-02	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	252	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	1FEMALE	null	The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.	null	Breast Cancer Low Bone Mineral Density Osteopenia	Breast Cancer Bone loss associated with Aromatase Inhibitor therapy (AIT) for non-metastatic BC osteopenia Low bone density	null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months intervention 2: 60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months	intervention 1: Placebo intervention 2: AMG 162 / Denosumab	0	null	249	0	0	0	NCT00089661	1COMPLETED	2009-05-27	2004-10-01	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 3 ]	16	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	The purpose of this study was to evaluate the safety and efficacy of afamelanotide (previously developed as CUV1647) as adjunctive therapy in patients undergoing photodynamic therapy using porfimer sodium.	null	Patients Undergoing Photodynamic Therapy Using Porfimer Sodium		null	2	arm 1: Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity. arm 2: Subjects visited the clinic on Day 0 (administratio...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: Afamelanotide intervention 2: Placebo	0	null	16	0	0	0	NCT04425746	1COMPLETED	2009-05-28	2008-08-05	Clinuvel Pharmaceuticals Limited	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 2 ]	26	NA	SINGLE_GROUP	2DIAGNOSTIC	0NONE	false	0ALL	false	The purpose of this study is to see if an antibody (cG250) attached to a radioactive substance (Iodine-124) safely detects clear cell renal cancer in patients with kidney tumors scheduled for surgery.	Antibodies are proteins made by the immune system. They fight things that the body sees as foreign, such as bacteria and viruses. The body can also see cancer cells as foreign. When the body sees a foreign invader, it sends out antibodies that tag the invader. Once this happens, the immune system can work to destroy wh...	Cancer of Kidney Kidney Cancer Renal Cancer Neoplasms, Kidney Renal Neoplasms Renal Cell Carcinoma (RCC) Clear Cell Renal Cell Carcinoma	Kidney Cancer Renal Cancer Neoplasms, Kidney cG250 antibody Iodine 124	null	1	arm 1: Patients who were scheduled for surgical resection of renal masses received a single intravenous (IV) dose of 10 mg of 5 milliCurie (mCi) /10 mg 124I-cG250. Patients underwent Positron-Emission Tomography/Computed Tomography (PET/CT) imaging of the whole body on at least 2 occasions: once following injection and...	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: 124-Iodine-cG250 (124I-cG250)	1	New York \| New York \| United States \| -74.00597 \| 40.71427	26	0	0	0	NCT00199888	1COMPLETED	2009-05-29	2005-06-01	Ludwig Institute for Cancer Research	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	287	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to assess the dose-response on the percent change from baseline in lumbar spine bone mineral density (BMD) at lumbar vertebrae 1 to 4 (L1- L4) when odanacatib (MK-0822) 10 mg, 25 mg, 50 mg or placebo is orally administered once weekly for 52 weeks to Japanese involutional osteoporosis parti...	null	Osteoporosis Postmenopausal		null	4	arm 1: After an observation period of \~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium \<1000 mg per day fro...	[ 2, 0, 0, 2 ]	4	[ 0, 7, 7, 0 ]	intervention 1: Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks. intervention 2: Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks. intervention 3: Calcium carbonate 500 mg tablet taken orally every day for 52 weeks. intervention...	intervention 1: Odanacatib intervention 2: Vitamin D3 intervention 3: Calcium carbonate intervention 4: Placebo	0	null	286	0	0	0	NCT00620113	1COMPLETED	2009-05-29	2007-12-03	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	616	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.	Patients will be enrolled at approximately 40 US investigative sites and receive vilazodone for 52 weeks of open label treatment. Safety measurements will include adverse events, vital signs, laboratory, ophthalmologic exams, Changes in Sexual Function Questionnaire (CSFQ) scale and electrocardiogram (ECG) findings col...	Major Depressive Disorder		null	1	arm 1: Vilazodone titrated up to 40 mg/day for 1 year.	[ 0 ]	1	[ 0 ]	intervention 1: titration to 40 milligrams (mg) every day (qd) for 1 year	intervention 1: vilazodone	38	Garden Grove \| California \| United States \| -117.94145 \| 33.77391 San Diego \| California \| United States \| -117.16472 \| 32.71571 Torrance \| California \| United States \| -118.34063 \| 33.83585 Upland \| California \| United States \| -117.64839 \| 34.09751 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Coral Spring...	599	1	0.001669	1	NCT00644358	1COMPLETED	2009-05-31	2007-12-31	Forest Laboratories	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.000295
[ 3 ]	25	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.	null	Psoriasis	psoriasis	null	3	arm 1: Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA. arm 2: Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1. arm 3: Patients with active stable plaq...	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: Ruxolitinib 1.5% cream BID for 28 days	intervention 1: Ruxolitinib	4	Fridley \| Minnesota \| United States \| -93.26328 \| 45.08608 Rochester \| New York \| United States \| -77.61556 \| 43.15478 Austin \| Texas \| United States \| -97.74306 \| 30.26715 College Station \| Texas \| United States \| -96.33441 \| 30.62798	50	0	0	0	NCT00617994	1COMPLETED	2009-05-31	2007-08-31	Incyte Corporation	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	517	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment (ART) regimens in ART-naive, human immunodeficiency virus, type 1 (HIV-1) infected participants. The primary objective of the study was to assess noninferiority of emtricitabine (FTC) and tenofovir disoproxil...	This study was originally planned as a 48-week, Phase 3, randomized, open-label, multicenter study comparing EFV+FTC+TDF (administered as the individual component drugs) versus CBV (lamivudine/zidovudine) + EFV to assess the efficacy and safety of both treatments in ART-Naive, HIV-1 infected participants. The regimen o...	HIV Infections	Human Immunodeficiency Virus	null	2	arm 1: Participants in this group received EFV 600 mg once daily + Combivir (\[CBV\]; the fixed dose combination pill containing lamivudine 150 mg + zidovudine 300 mg) taken twice daily from the start of the study until Week 144. At Week 144 all participants who opted to roll over into the additional 96-week study exte...	[ 1, 0 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: Capsule containing 200 mg FTC, taken once daily, for 96 weeks intervention 2: Tablet containing 300 mg TDF, taken once daily, for 96 weeks intervention 3: Tablet containing 600 mg EFV, taken once daily, for 96 weeks intervention 4: Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once dai...	intervention 1: Emtricitabine (FTC) intervention 2: Tenofovir Disoproxil Fumarate (TDF) intervention 3: Efavirenz (EFV) intervention 4: FTC/TDF intervention 5: FTC/TDF/EFV intervention 6: Lamivudine/zidovudine	5	Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Huntersville \| North Carolina \| United States \| -80.84285 \| ...	957	2	0.00209	1	NCT00112047	1COMPLETED	2009-06-01	2003-07-01	Gilead Sciences	4INDUSTRY	false	false	false	null	0	0	2	0	0	0.000573
[ 4 ]	463	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options (i.e., patients who developed progressive disease or relapsed while on or after prior fluoropyr...	null	Colorectal Cancer Metastases	Metastatic Colorectal Cancer, Colon Colorectal, Rectal Cancer, Cancer Metastatic, EGFr, Clinical Trial Panitumumab, ABX-EGF Immunex, Abgenix, Amgen	null	2	arm 1: Panitumumab will be administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants develop progressive disease or are unable to tolerate study drug. Participants will also receive best supportive care (BSC) as judged appropriate by the investigator and according to institutional ...	[ 0, 5 ]	2	[ 10, 0 ]	intervention 1: Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception ...	intervention 1: Best supportive care intervention 2: Panitumumab	0	null	463	1	0.00216	1	NCT00113763	1COMPLETED	2009-06-01	2004-01-01	Amgen	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.000381
[ 4 ]	344	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	To provide treatment to eligible subjects who have successfully completed one of the following phase III ziprasidone studies, A1281028, A1281044, A1281045 (NCT00136994) or A1281088 (NCT00143351).	null	Schizophrenia	Open-label extension Ziprasidone study in Schizophrenia	null	0	null	null	1	[ 0 ]	intervention 1: 20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.	intervention 1: Ziprasidone	87	Sora \| Frosinone \| Italy \| 13.61356 \| 41.71829 Parma \| PR \| Italy \| 10.32618 \| 44.79935 Acri, CS \| N/A \| Italy \| 16.38635 \| 39.49624 Arezzo \| N/A \| Italy \| 11.88068 \| 43.46276 Arona (No) \| N/A \| Italy \| 8.55715 \| 45.7589 Bassano del Grappa \| N/A \| Italy \| 11.72739 \| 45.76656 Bisceglie (BA) \| N/A \| Italy \| 16.50104 \| 41...	331	3	0.009063	1	NCT00139737	1COMPLETED	2009-06-01	2002-03-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	0	1	2	0	0	0.003087
[ 5 ]	2,252	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This single arm study will assess the safety and efficacy of Avastin combined with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Avastin will be given as first-line treatment in combination with platinum-based chemotherapy or in combina...	null	Non-Squamous Non-Small Cell Lung Cancer		null	1	arm 1: Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chem...	[ 0 ]	2	[ 0, 0 ]	intervention 1: As prescribed intervention 2: 15 mg/kg IV on Day 1 of each 3 week cycle	intervention 1: Platinum-based chemotherapy intervention 2: Bevacizumab [Avastin]	369	Buenos Aires \| N/A \| Argentina \| -58.37723 \| -34.61315 Chaco-resistencia \| N/A \| Argentina \| N/A \| N/A Córdoba \| N/A \| Argentina \| -64.18853 \| -31.40648 Córdoba \| N/A \| Argentina \| -64.18853 \| -31.40648 San Miguel de Tucumán \| N/A \| Argentina \| -65.21051 \| -26.81601 St Leonards \| New South Wales \| Australia \| 151.19836...	2,212	2	0.000904	1	NCT00451906	1COMPLETED	2009-06-01	2006-08-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	1	0	0	0	1	0.000248
[ 4 ]	1,467	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.	This study consists of a double-blind, double-dummy, parallel-group comparison of 23 mg donepezil SR with the currently marketed donepezil formulation (10 mg donepezil IR) in patients with moderate to severe Alzheimer's disease. Patients must have been taking 10 mg IR (or a bioequivalent generic) for at least 3 months ...	Alzheimer's Disease	Moderate to Severe Alzheimer's Disease	null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design: 23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation. intervention 2: Patients will receive study medication orally, once daily, for 24 weeks...	intervention 1: Aricept (donepezil SR 23 mg) intervention 2: Aricept (donepezil IR 10 mg)	1	Hickory \| North Carolina \| United States \| -81.3412 \| 35.73319	1,434	1	0.000697	1	NCT00478205	1COMPLETED	2009-06-01	2007-06-01	Eisai Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.000123
[ 5 ]	289	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	false	0ALL	null	Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion. Main Secondary objectives: To compare insulin glulisine, insulin aspart and insulin lispro on: * Unexplained ...	The maximal duration of the study participation for patients was 41 weeks and one day, split in: * a 2-week screening period, * a 39-week treatment period: 3 treatment periods of 13 weeks with a crossover alternative regimen, including a dose adjustment period of 1 week at the beginning of each period (sequence1: insu...	Diabetes Mellitus, Type 1		null	3	arm 1: sequence 1: insulin glulisine / insulin aspart / insulin lispro. arm 2: Sequence 2: insulin aspart / insulin lispro / insulin glulisine arm 3: Sequence 3: insulin lispro / insulin glulisine / insulin aspart	[ 0, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump intervention 2: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump intervention 3: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump	intervention 1: Insulin glulisine intervention 2: Insulin lispro intervention 3: Insulin aspart	12	Bridgewater \| New Jersey \| United States \| -74.64815 \| 40.60079 Macquarie Park \| N/A \| Australia \| 151.12757 \| -33.78105 Vienna \| N/A \| Austria \| 16.37208 \| 48.20849 Paris \| N/A \| France \| 2.3488 \| 48.85341 Budapest \| N/A \| Hungary \| 19.04045 \| 47.49835 Netanya \| N/A \| Israel \| 34.85992 \| 32.33291 Milan \| N/A \| Italy \|...	809	2	0.002472	1	NCT00607087	1COMPLETED	2009-06-01	2008-01-01	Sanofi	4INDUSTRY	false	false	false	null	0	0	0	0	2	0.000678
[ 4 ]	2,322	RANDOMIZED	PARALLEL	1PREVENTION	2DOUBLE	false	0ALL	null	The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.	null	Chemotherapy-Induced Nausea and Vomiting (CINV)		null	2	arm 1: Arm 1: study medication arm 2: Arm 2: Active comparator	[ 0, 1 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1. intervention 2: Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3). intervention 3: Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4. intervention 4: Oral do...	intervention 1: Comparator: fosaprepitant dimeglumine intervention 2: Comparator: Aprepitant intervention 3: Dexamethasone intervention 4: Dexamethasone intervention 5: Ondansetron	0	null	2,312	24	0.010381	1	NCT00619359	1COMPLETED	2009-06-01	2008-02-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	24	0	0	0	0	0.006986
[ 3 ]	35	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to test if intravenous sulopenem and an oral drug, PF-03709270 are safe and effective in patients that are hospitalized with community acquired pneumonia.	null	Pneumonia, Bacterial		null	3	arm 1: Loading dose of IV sulopenem with switch to oral PF-03709270 arm 2: IV sulopenem with switch to oral PF-03709270 arm 3: IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day intervention 2: Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day intervention 3: IV ceftriaxone (2g) infused ove...	intervention 1: sulopenem and PF-03709270 intervention 2: Sulopenem and PF-03709270 intervention 3: Ceftriaxone and amoxicillin/clavulanate	24	Chula Vista \| California \| United States \| -117.0842 \| 32.64005 Chula Vista \| California \| United States \| -117.0842 \| 32.64005 Oceanside \| California \| United States \| -117.37948 \| 33.19587 Oceanside \| California \| United States \| -117.37948 \| 33.19587 Moline \| Illinois \| United States \| -90.51513 \| 41.5067 Rock Islan...	33	1	0.030303	1	NCT00797108	1COMPLETED	2009-06-01	2009-01-01	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	1	0	0.005369
[ 2, 3 ]	54	null	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant or intolerant to treatment and will continue study drug after completing the previous Phase ...	null	Chronic Myelogenous Leukemia Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia		null	3	arm 1: CML - Chronic Phase arm 2: CML - Accelerated Phase and Blast Phase arm 3: Ph+ Acute Lymphoblastic Leukemia	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID	intervention 1: dasatinib	0	null	54	1	0.018519	1	NCT01030718	1COMPLETED	2009-06-01	2006-01-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0	0	0	0	1	0.003276
[ 3 ]	2	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Although used primarily to treat malignant disorders of the blood, allogeneic stem cell transplantation can also cure a variety of non-cancerous, inherited or acquired disorders of the blood. Unfortunately, the conventional approach to allogeneic stem cell transplantation is a risky procedure. For some non-c...	OBJECTIVES: Primary Objective(s): 1. Evaluate the feasibility in terms of mortality, occurrence of acute graft versus host disease, and grades 3-4/4 toxicity of in vivo and in vitro Campath coupled with concomitantly administered nonmyeloablative fludarabine, cyclophosphamide and total body irradiation (TBI) followed...	Sickle Cell Anemia Severe Aplastic Anemia Paroxysmal Nocturnal Hemoglobinuria (PNH) Pure Red Cell Aplasia	sickle cell anemia severe aplastic anemia	null	2	arm 1: Campath, Chemo and/or TBI Allo SCT arm 2: Campath, Chemo and/or TBI Allo SCT	[ 0, 0 ]	1	[ 0 ]	intervention 1: Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.	intervention 1: Campath, Chemo and/or TBI Allo SCT	2	Orlando \| Florida \| United States \| -81.37924 \| 28.53834 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	2	0	0	0	NCT00004143	1COMPLETED	2009-06-01	1999-09-01	David Rizzieri, MD	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	29	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Donor: This clinical study will evaluate the feasibility of a purified CD34 peripheral blood progenitor cell (PBPC) transplants in patients with hematological malignancies. The primary objectives of the study are to evaluate the recipient obtaining donor derived neutrophil engraftment and the incidence of acute graft...	Donor Description: Before taking part in this study, donors will have an evaluation that is the standard for any bone marrow or blood stem cell donor. These include standard blood tests, an electrocardiogram (EKG), and a chest X-ray. Donors will also be given a general health questionnaire that is given to all blood d...	Leukemia Lymphoma	Acute Myelogenous Leukemia Acute Lymphocytic Leukemia Myelodysplastic Syndrome Chronic Lymphocytic Leukemia Leukemia Lymphoma Non Hodgkin's Lymphoma T cell depletion CD34 selected progenitors cell GVHD	null	1	arm 1: CD34 peripheral blood progenitor cell (PBPC) transplants in 3 groups: 1) HLA-matched Sibling Transplant Patients; 2) Unrelated Donor Transplant Patients; 3) Haplo Identical Transplant Patients. Preparative regimen is 140 mg/m\^2 Melphalan on day -8, 10 mg/kg Thiotepa on day -7, 160 mg/m\^2 Fludarabine over 4 day...	[ 0 ]	5	[ 3, 0, 0, 0, 0 ]	intervention 1: Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0. intervention 2: 140 mg/m\^2 on day -8 intervention 3: 10 mg/kg on day -7 intervention 4: 160 mg/m\^2 over 4 days on days -6, -5, -4, -3 intervention 5: 1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.	intervention 1: Megadose of CD34 Selected Progenitor Cells intervention 2: Melphalan intervention 3: Thiotepa intervention 4: Fludarabine intervention 5: Rabbit ATG	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	28	0	0	0	NCT00038857	1COMPLETED	2009-06-01	2001-09-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	156	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®), venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which is more effective in treating major depression.	MDD is one of the most prevalent psychiatric disorders. Different forms of psychotherapy for depression have been found effective. This study compares a form of dynamic psychotherapy called supportive-expressive psychotherapy to medication and to placebo. Participants are evaluated on 2 occasions, 1 week apart, before...	Depression	Major Depressive Disorder	null	3	arm 1: Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8 arm 2: Participants will receive supportive-expressive psychotherapy. arm 3: Participants receive placebo.	[ 0, 1, 2 ]	4	[ 5, 0, 0, 0 ]	intervention 1: The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship. intervention 2: Participants will receive sertraline. intervention 3: Participants will receive a pill placebo. intervention 4: Participants wil...	intervention 1: Supportive Expressive Therapy intervention 2: Sertraline intervention 3: Pill Placebo intervention 4: Venlafaxine	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	156	0	0	0	NCT00043550	1COMPLETED	2009-06-01	2001-11-01	University of Pennsylvania	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	449	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar trihydrochloride, a modulator of multidrug resistance (MDR), may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet k...	OBJECTIVES: * Compare the overall survival and progression-free survival of elderly patients with newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts (RAEB) in transformation, or high-risk RAEB treated with daunorubicin and cytarabine with or without zosuquidar trihydrochloride. * Compare the ...	Leukemia Myelodysplastic Syndromes	adult acute monocytic leukemia (M5b) adult acute erythroid leukemia (M6) adult acute megakaryoblastic leukemia (M7) adult acute myeloblastic leukemia with maturation (M2) adult acute myeloblastic leukemia without maturation (M1) adult acute myelomonocytic leukemia (M4) adult acute monoblastic leukemia (M5a) refractory ...	null	2	arm 1: Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction. arm 2: Induction treatment with daunorub...	[ 0, 1 ]	6	[ 2, 2, 0, 0, 0, 0 ]	intervention 1: 250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size. intervention 2: 5 μg/kg/day by e...	intervention 1: filgrastim intervention 2: sargramostim intervention 3: cytarabine intervention 4: daunorubicin hydrochloride intervention 5: zosuquidar trihydrochloride intervention 6: Placebo	92	Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Boulder \| Colorado \| United States \| -105.27055 \| 40.01499 Colorado Springs \| Colorado \| United States \| -104.82136 \| 38.83388 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Denver \| Colorado...	750	0	0	0	NCT00046930	1COMPLETED	2009-06-01	2002-09-17	Eastern Cooperative Oncology Group	5NETWORK	false	false	false	null	0	0	0	0	0	0
[ 3 ]	7	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This study will examine the safety and effectiveness of peginterferon alpha-2b (PEG-Intron) alone and together with thalidomide in patients with gliomas (a type of brain tumor). Gliomas are nourished by blood delivered through blood vessels whose formation is stimulated by substances produced by the tumor itself. Stopp...	Background: There is a growing belief that angiogenesis inhibition represents a potentially promising, novel therapeutic approach to highly vascular solid tumors like malignant gliomas. Thalidomide and Peg-Intron (IFN - Interferon) are attractive drugs to use in combination to test the hypothesis of combination anti-a...	Glioma	Brain Tumors Experimental Toxicities Efficacy Progression-Free Brain Tumor Glioma	null	2	arm 1: Glioblastoma multiforme is one of the most common and aggressive types of brain tumor. arm 2: Anaplastic glioma is a type of brain tumor that develops from star-shaped glial cells that support nerve cells. Anaplastic oligodendroglioma is a malignant type of brain tumor sensitive to treatment with chemotherapy an...	[ 5, 5 ]	2	[ 2, 0 ]	intervention 1: 0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection intervention 2: Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.	intervention 1: PEG-interferon alfa-2b intervention 2: Thalidomide	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	7	0	0	0	NCT00047879	1COMPLETED	2009-06-01	2002-10-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 4 ]	101	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. It is not yet...	OBJECTIVES: Compare local control, failure-free survival, and overall survival of patients with locally advanced carcinoma of the cervix treated with cisplatin and radiotherapy alone, versus cisplatin and radiotherapy with hyperthermia . OUTLINE: This is a randomized, multicenter study. Patients are stratified accor...	Cervical Cancer	stage IA cervical cancer stage IB cervical cancer stage IIA cervical cancer stage IIB cervical cancer stage III cervical cancer stage IVA cervical cancer cervical adenocarcinoma cervical adenosquamous cell carcinoma cervical squamous cell carcinoma	null	2	arm 1: Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of...	[ 0, 1 ]	4	[ 0, 3, 4, 4 ]	intervention 1: Given IV intervention 2: Patients undergo hyperthermia treatment over 60-90 minutes intervention 3: Patients undergo brachytherapy for 2-3 days intervention 4: Patients undergo external beam radiation therapy once daily on days 1-5	intervention 1: cisplatin intervention 2: hyperthermia treatment intervention 3: brachytherapy intervention 4: external beam radiation therapy	1	Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	101	0	0	0	NCT00085631	6TERMINATED	2009-06-01	2003-03-01	Mark Dewhirst	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	260	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	0ALL	true	The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment com...	The study compared a minimal level counseling model to a higher level counseling model plus one of two types of FDA approved smoking cessation products (bupropion or the nicotine patch)used to achieve long term abstinence among lighter smokers. Each participant received both products under blinded conditions meaning th...	Tobacco Use Disorder	light smokers, smoking cessation treatment programs	null	4	arm 1: bupropion and MM counseling with placebo patch arm 2: bupropion and Mayo counseling with placebo patch. arm 3: patch and MM counseling with placebo pills arm 4: patch and Mayo counseling with placebo pills	[ 0, 0, 2, 0 ]	6	[ 0, 0, 5, 5, 0, 0 ]	intervention 1: starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks. intervention 2: 150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks intervention 3: Brief manual based therapy; four 15 minute session over 10 weeks. intervention 4: Manual ...	intervention 1: nicotine transdermal system intervention 2: bupropion intervention 3: Medication Management intervention 4: Mayo Counseling intervention 5: placebo patch intervention 6: placebo bupropion	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	260	0	0	0	NCT00086411	1COMPLETED	2009-06-01	2003-09-01	University of Pennsylvania	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	40	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent and/or metastatic adenoid cystic cancer or other salivary gland cancers. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.	PRIMARY OBJECTIVES: I. To determine the antitumor activity of GW572016 in recurrent and/or metastatic adenoid cystic carcinoma of the salivary glands using objective response rates (partial and complete responses). SECONDARY OBJECTIVES: I. To determine the duration of objective response, rate and duration of stable ...	High-grade Salivary Gland Carcinoma High-grade Salivary Gland Mucoepidermoid Carcinoma Low-grade Salivary Gland Carcinoma Low-grade Salivary Gland Mucoepidermoid Carcinoma Recurrent Adenoid Cystic Carcinoma of the Oral Cavity Recurrent Salivary Gland Cancer Salivary Gland Acinic Cell Tumor Salivary Gland Adenocarcinoma...		null	1	arm 1: Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.	[ 0 ]	2	[ 0, 10 ]	intervention 1: Given orally intervention 2: Correlative studies	intervention 1: lapatinib ditosylate intervention 2: laboratory biomarker analysis	1	Toronto \| Ontario \| Canada \| -79.39864 \| 43.70643	39	0	0	0	NCT00095563	1COMPLETED	2009-06-01	2004-09-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0	0	0	0	0	0
[ 0 ]	8,164	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	true	The VITATOPS study is a multi-center, randomized, double blind, placebo-controlled secondary stroke prevention trial to determine whether the addition of vitamin supplements (B12 500 ug, B6 25 mg, Folate 2 mg) to best medical/surgical management (including modification of risk factors) will reduce the combined incidenc...	Background: Epidemiological studies suggest that raised plasma concentrations of total homocysteine (tHcy) may be a common, causal and treatable risk factor for atherothromboembolic ischemic stroke, dementia and depression. Although tHcy can be lowered effectively with small doses of folic acid, vitamin B12 and vitamin...	Stroke Transient Ischemic Attack	VITATOPS stroke prevention multivitamins homocysteine	null	2	arm 1: Active Treatment Arm: VITATOPS study tablet (folate 2 mg, B6 25 mg, B12 500 ug). Taken daily for the duration of the study. arm 2: Placebo Treatment Arm: The placebo tablet will have the same appearance, taste and texture as the vitamin preparation and contains excipients, coating and coating aids.	[ 1, 2 ]	2	[ 0, 10 ]	intervention 1: multivitamin intervention 2: None	intervention 1: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo intervention 2: Placebo	111	New York \| New York \| United States \| -74.00597 \| 40.71427 Abington \| Pennsylvania \| United States \| -75.11795 \| 40.12067 Columbia \| South Carolina \| United States \| -81.03481 \| 34.00071 Columbia \| South Carolina \| United States \| -81.03481 \| 34.00071 Gosford \| N/A \| Australia \| 151.34399 \| -33.4244 New South Wales \| N...	8,164	0	0	0	NCT00097669	1COMPLETED	2009-06-01	1998-11-01	VITATOPS	2OTHER_GOV	false	false	false	null	0	0	0	0	0	0
[ 2, 3 ]	39	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication. Study hypothesis: Three months of fish oil supplementation will improve depression scores on the Montgomery-Asberg depression ...	Depression occurs in 50% to 60% of all individuals with MS. Evidence suggests that the omega-3 fatty acids in fish oil supplements can significantly reduce depression with a low risk of side effects. Therefore, fish oil supplements may be a safe adjunctive therapy to improve the therapeutic benefits of antidepressants....	Multiple Sclerosis Depression	Fatty Acids, Omega-3 Fish Oils Complementary Therapies	null	2	arm 1: Fish oil concentrate arm 2: Placebo oil	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA). intervention 2: soybean oil with 1% fish oil at a daily dose of 6 grams	intervention 1: Fish oil concentrate intervention 2: Placebo	1	Portland \| Oregon \| United States \| -122.67621 \| 45.52345	39	0	0	0	NCT00122954	1COMPLETED	2009-06-01	2005-07-01	Oregon Health and Science University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	27	NON_RANDOMIZED	PARALLEL	7BASIC_SCIENCE	2DOUBLE	true	0ALL	false	The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.	Prescription opioid abuse is becoming an increasingly widespread and serious public health concern. The 2001 National Household Survey on Drug Abuse report revealed that the number of first-time users of prescription opioid medications for non-medical reasons reached 2 million in the year 2000, a number that has quintu...	Opioid-Related Disorders Substance-Related Disorders	Opiate Opioid Abuse Liability Abuse Potential	null	2	arm 1: Recreational users of prescription opioids. Participants in this arm received the 3 interventions (0, 15, and 30 mg oxycodone) at random. arm 2: Participants with a history of prescription opioid use, but who did not abuse them. Participants in this arm received the 3 interventions (0, 15, and 30 mg) at random.	[ 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: 15 mg/70 kg oxycodone administered once per day, orally. intervention 2: 30 mg/70 kg oxycodone administered once per day, orally. intervention 3: 0 mg placebo dose administered once a day, orally.	intervention 1: oxycodone 15 mg intervention 2: oxycodone 30 mg intervention 3: Placebo 0 mg	1	New York \| New York \| United States \| -74.00597 \| 40.71427	27	0	0	0	NCT00158184	1COMPLETED	2009-06-01	2004-06-01	New York State Psychiatric Institute	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	38	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The investigators propose that treatment of the comorbid disorders (depression, anxiety, and impulsivity) with sertraline in patients with lone psychogenic nonepileptic seizures (NES), will result in a decreased number of NES. The purpose of this study is to provide pilot testing and data to inform the future randomize...	This is a pilot, prospective, single center, randomized, placebo-controlled, double-blind trial, that assesses the number of NES in patients treated with flexible dose sertraline (Zoloft). This study will provide outcomes data and the effect size necessary for a future R01, multi-center randomized control trial. Second...	Convulsion, Non-Epileptic Conversion Disorder Depression Stress Disorders, Post-Traumatic	nonepileptic seizure pseudoseizure conversion disorder psychogenic Depression Anxiety Abuse post-traumatic stress disorder sertraline serotonin randomized controlled trial	null	2	arm 1: flexible dose sertraline, 25 to 200mg titration as tolerated, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES arm 2: flexible dose placebo, administered over 12 weeks with a two week untreated lead in period monitoring their baseline NES	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: flexible dose sertraline intervention 2: flexible dose placebo	intervention 1: sertraline intervention 2: placebo	1	Providence \| Rhode Island \| United States \| -71.41283 \| 41.82399	38	0	0	0	NCT00159965	1COMPLETED	2009-06-01	2003-12-01	Rhode Island Hospital	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	97	NA	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	true	This study will evaluate changes in brain energy metabolism due to treatment with escitalopram in people with major depressive disorder.	Major depressive disorder (MDD) is a severe form of depression. MDD can significantly interfere with an individual's thoughts, behavior, mood, and physical health. People who suffer from MDD often experience feelings of worthlessness; they may feel hopeless and may be unable to cope with problems in their life. In addi...	Depression	Brain Bioenergetic Metabolism Magnetic Resonance Spectroscopy Major Depressive Disorder Treatment Response	null	1	arm 1: Participants will receive open treatment with escitalopram.	[ 0 ]	1	[ 0 ]	intervention 1: Escitalopram 10 to 30 mg per day for 12 weeks	intervention 1: Escitalopram	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	97	0	0	0	NCT00183677	1COMPLETED	2009-06-01	2003-07-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	35	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This study will evaluate the effectiveness of memantine in improving rehabilitation outcomes and preventing major depressive disorder in older adults who have been admitted to a rehabilitation hospital for a hip fracture or cardiopulmonary condition.	Depression is a serious medical illness that is often difficult to diagnose and treat. It occurs in people of all ages, but is often overlooked in older adults. Depression frequently co-occurs with other serious illnesses, and may be mistaken by both patients and health care givers as a normal consequence of the illnes...	Depression	Major depressive disorder Rehabilitating Elderly Apathy	null	2	arm 1: Memantine for 12 weeks arm 2: Placebo for 12 weeks	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day. intervention 2: Placebo distribution is planned to mimic the active drug.	intervention 1: Memantine intervention 2: Placebo	1	Pittsburgh \| Pennsylvania \| United States \| -79.99589 \| 40.44062	35	0	0	0	NCT00183729	1COMPLETED	2009-06-01	2005-08-01	Eric Lenze	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	198	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.	Upon determination of eligibility, all patients will be randomly assigned to one of two treatment arms: * Paclitaxel + Carboplatin + Etoposide * Irinotecan + Gemcitabine Patients will be stratified by tumor location (liver/bone versus all others) and number of metastatic sites (one versus two or more). Patients with ...	Neoplasms, Unknown Primary	Neoplasms, Unknown Primary	null	2	arm 1: Paclitaxel 200 mg/m2 by 1-hour IV infusion, day 1 Carboplatin area under the curve (AUC) 6.0 IV, day 1 Etoposide 50 mg alternating with 100 mg by mouth, days 1 and 10 Regimen A was repeated at a 21-day interval arm 2: Irinotecan 100 mg/m2 IV, days 1 and 8 Gemcitabine 1000 mg/m2 IV, days 1 and 8 Regimen B wa...	[ 0, 0 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: 50 mg alternating with 100 mg PO, days 1 and 10 in regimen A intervention 2: 1000 mg/m2 IV, days 1 and 8, in regimen B intervention 3: 1000 mg/m2 IV days 1 and 8 in regimen B intervention 4: 200 mg/m2 by 1-hour IV infusion, day 1, regimen A intervention 5: Area under the curve (AUC) 6.0 IV, day 1, regim...	intervention 1: Etoposide intervention 2: Gemcitabine intervention 3: Irinotecan intervention 4: Paclitaxel intervention 5: Carboplatin	31	Anniston \| Alabama \| United States \| -85.83163 \| 33.65983 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Jonesboro \| Arkansas \| United States \| -90.70428 \| 35.8423 Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Lakeland \| Florida \| ...	198	0	0	0	NCT00193596	1COMPLETED	2009-06-01	2003-09-01	SCRI Development Innovations, LLC	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	132	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will test the hypothesis that administration of granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with acute lung injury/acute respiratory distress syndrome (ALI/ARDS) will improve the clinical course and outcome by shortening the duration of mechanical ventilation for these patients.	BACKGROUND: Respiratory failure due to ALI/ARDS remains a major health problem, despite significant progress in intensive care unit care and ventilator management. ALI/ARDS is characterized by unacceptably high mortality despite enormous expenditure of health care resources. Survivors face long-term consequences that ...	Respiratory Distress Syndrome, Adult		null	2	arm 1: Participants will be randomized to receive recombinant human GM-CSF (250 mcg/M2). arm 2: Participants will be randomized to receive placebo.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Placebo will be administered by slow intravenous infusion once daily for 14 days. intervention 2: Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.	intervention 1: Placebo intervention 2: GM-CSF	3	Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756	130	0	0	0	NCT00201409	1COMPLETED	2009-06-01	2004-07-01	University of Michigan	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	46	NON_RANDOMIZED	PARALLEL	1PREVENTION	0NONE	true	1FEMALE	null	Oral contraceptives (OCs) are the most widely used method of reversible birth control. However, the long-term cardiovascular safety of the widely used low-dose OCs (ethinyl-estradiol \< 50 mcg) is still debated. Although cardiovascular events are rare in young women whether they use OCs or not, the risks of myocardial ...	null	Metabolic Syndrome X Insulin Resistance Obesity Cardiovascular Diseases	Inflammatory markers, oral contraceptions, obesity, metabolic syndrome X	null	3	arm 1: None arm 2: None arm 3: None	[ 1, 1, 1 ]	1	[ 0 ]	intervention 1: Ortho Tri Cyclen, one tablet daily, for 6 cycles	intervention 1: Ortho Tri Cyclen	1	Richmond \| Virginia \| United States \| -77.46026 \| 37.55376	36	0	0	0	NCT00205504	1COMPLETED	2009-06-01	2005-06-01	Virginia Commonwealth University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	19	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of the study is to assess the safety and efficacy of mycophenolate mofetil alone, or with reduced dose cyclosporine (CsA) or tacrolimus, for immunosuppression long-term after liver transplantation, in an attempt to reduce the potential side effects from using cyclosporine or tacrolimus.	Most liver transplant recipients receive an immunosuppressive drug regimen that contains either cyclosporine or tacrolimus. Although these drugs have revolutionized transplantation, in many patients their long-term use is a major cause of serious side effects, including kidney failure, hypertension, diabetes mellitus, ...	Liver Disease	Liver transplantation Calcineurin inhibitor withdraw mycophenolate mofetil Immunosuppression side effects Graft rejection	null	2	arm 1: mycophenolate mofetil monotherapy arm 2: mycophenolate mofetil and half their baseline dose of calcineurin inhibitor	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: mycophenolate mofetil and half their baseline dose of calcineurin inhibitor intervention 2: mycophenolate mofetil monotherapy	intervention 1: mycophenolate mofetil intervention 2: mycophenolate mofetil	3	Lexington \| Kentucky \| United States \| -84.47772 \| 37.98869 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 San Antonio \| Texas \| United States \| -98.49363 \| 29.42412	19	0	0	0	NCT00206076	1COMPLETED	2009-06-01	2006-08-01	Albert Einstein Healthcare Network	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	17	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The research project is a controlled pilot study of the efficacy of cognitive-behavioral therapy (CBT) as an adjunct to serotonin reuptake inhibitor (SRI) pharmacotherapy in body dysmorphic disorder (BDD). This study assesses the efficacy of CBT in comparison to relaxation and stress management training (RSMT), an acti...	In total, 20 BDD patients aged 16 through 65 will participate. To be eligible they must meet DSM-IV criteria for BDD, have a score of 20 or greater on the BDD modification of the Yale Brown Obsessive-Compulsive Scale (BDD-YBOCS) and be on a stable, therapeutic does of an SRI (at least 12 weeks on the SRI with 8 weeks a...	Body Dysmorphic Disorder	Body Dysmorphic Disorder SRIs Cognitive Behavioral Therapy	null	1	arm 1: Participants with body dysmorphic disorder	[ 0 ]	2	[ 5, 0 ]	intervention 1: standard psychiatric evaluation intervention 2: start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.	intervention 1: Cognitive Behavioral Therapy intervention 2: Venlafaxine	1	New York \| New York \| United States \| -74.00597 \| 40.71427	17	0	0	0	NCT00211809	6TERMINATED	2009-06-01	2008-09-01	Icahn School of Medicine at Mount Sinai	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	264	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	1FEMALE	true	The purpose of this study is to evaluate the efficacy of the glycine antagonist, GW468816, compared with placebo on duration of abstinence and rates of relapse in recently quit female smokers in a randomized, double-blind, five-week clinical trial. According to the investigators, the new medication, GW468816, is thoug...	Smoking is the leading cause of preventable mortality in developed countries. Pharmacotherapy, including bupropion and nicotine replacement therapy (NRT), is universally recommended for smoking cessation treatment; however, even with treatment, the majority of smokers either fail to quit in the short term or relapse in...	Nicotine Dependence	Drugs, Investigational Therapies for Relapse to Nicotine Relapse Prevention Nicotine Cessation Therapies Smoking Cessation Nicotine Dependence	null	2	arm 1: Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial arm 2: Placebo, 200 mg/day, for a 5-week trial	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Pharmacotherapies for Relapse Prevention intervention 2: None	intervention 1: GW468816 intervention 2: Placebo Comparator: Placebo	2	Belmont \| Massachusetts \| United States \| -71.17867 \| 42.39593 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	98	0	0	0	NCT00218465	1COMPLETED	2009-06-01	2006-08-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	247	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to compare the rates of Progression-Free Survival (PFS) at 12 months for patients treated with Bev-FOLFOX versus patients treated with FOLF-CB for first line treatment of metastatic colorectal cancer.	This is a Phase III, open label, nonblinded study. A total of 240 eligible patients will be randomized on a 1:1 basis to either treatment Arm. In this trial, we will compare the efficacy, safety, and tolerability of this novel combination of biweekly infusional 5-FU/leucovorin plus cetuximab and bevacizumab (FOLF-CB) ...	Metastatic Colorectal Cancer		null	2	arm 1: (Bev-FOLFOX): Bevacizumab, followed by oxaliplatin and LV given simultaneously via "T" connector over 2 hours, followed by bolus 5-FU followed by infusional 5-FU. Bevacizumab --\> oxaliplatin and LV --\> bolus 5-FU --\> infusional 5-FU Dosing on Days 1 and 15 of each 28-day cycle arm 2: (FOLF-CB): Cetuximab ad...	[ 0, 0 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: 5 mg/kg over 30 minutes on Days 1 and 15 intervention 2: 85 mg/m2 on Days 1 and 15 intervention 3: 400 mg/m2 on Days 1 and 15 intervention 4: 400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour pe...	intervention 1: Bevacizumab intervention 2: Oxaliplatin intervention 3: Leucovorin intervention 4: Fluorouracil intervention 5: Cetuximab	82	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Sedona \| Arizona \| United States \| -111.76099 \| 34.86974 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Fresno \| California \| United States \| -119.77237 \| 36.74773 Monterey \| California \| Unit...	239	0	0	0	NCT00252564	1COMPLETED	2009-06-01	2005-09-01	US Oncology Research	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	1,174	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline	null	Parkinson's Disease	Parkinson's Rasagiline Mesylate	null	3	arm 1: 1mg early start active treatment arm (72 weeks active)followed by 1mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 weeks active) arm 2: 2mg early start active treatment arm (72 weeks active)followed by 2mg 36 week delayed start active treatment arm (36 weeks placebo followed by 36 ...	[ 0, 0, 2 ]	3	[ 0, 0, 10 ]	intervention 1: tablet, 1mg once daily intervention 2: tablet, 2mg once daily intervention 3: Placebo	intervention 1: Rasagiline Mesylate intervention 2: Rasagiline Mesylate intervention 3: Placebo	0	null	1,174	0	0	0	NCT00256204	1COMPLETED	2009-06-01	2005-11-01	Teva Branded Pharmaceutical Products R&D, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	755	RANDOMIZED	FACTORIAL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine wh...	The ultimate goal of RA is to eliminate symptoms, restoring the patient to normal physical, social, emotional, and vocational function, and preserving the structure and integrity of joints. While disease modifying anti-rheumatic drugs (DMARDs) have long been the cornerstone of RA therapy, the limitations of DMARDs have...	Rheumatoid Arthritis	RA painful joints swollen joints	null	4	arm 1: methotrexate (MTX) + etanercept arm 2: methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) arm 3: methotrexate (MTX) or MTX + Etanercept arm 4: methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ)	[ 1, 1, 1, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: varies intervention 2: varies intervention 3: varies intervention 4: varies	intervention 1: methotrexate intervention 2: sulfasalazine intervention 3: hydroxychloroquine intervention 4: etanercept	1	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066	755	0	0	0	NCT00259610	1COMPLETED	2009-06-01	2004-05-01	University of Alabama at Birmingham	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	221	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in adolescents (ages 13-17) with schizophrenia.	On March 24, 2009, Pfizer Inc. stopped late stage Geodon pediatric clinical trials in schizophrenia (A1281134 - placebo controlled; A1281135 - open label). As recommended by the DSMB, these studies were stopped due to lack of efficacy. No safety concerns were identified.	Schizophrenia	Adolescent Subjects	null	1	arm 1: None	[ 5 ]	1	[ 0 ]	intervention 1: Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.	intervention 1: Ziprasidone oral capsules	68	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 San Diego \| California \| United States \| -117.16472 \| 32.71571 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 Washington D.C. \| Di...	221	0	0	0	NCT00265382	6TERMINATED	2009-06-01	2006-06-01	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	60	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	false	Currently, when a child has fever either ibuprofen (e.g. Motrin, Advil) or acetaminophen (e.g. Tylenol) is given. Both Ibuprofen and Acetaminophen are approved for over the counter use for treatment of fever by the Food and Drug Administration (FDA). This study hopes to determine whether giving both medications togethe...	Despite a lack of evidence to support their fears, a majority of parents, pediatricians, and pediatric nurses believe that fever can be dangerous to a child. This "fever phobia" has caused a majority of caregivers to aggressively treat fever with antipyretics such as ibuprofen and acetaminophen, often in combination. A...	Fever	fever treatment children	null	3	arm 1: At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) arm 2: At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and an appropriate dose of Acetaminophen (15 mg/kg) arm 3: At time 0 child is given an appropriate dose of Ibuprofen (10mg/kg) and at time 3 hours is given an appropriate...	[ 1, 0, 0 ]	2	[ 0, 0 ]	intervention 1: Given for fever control 15mg/kg intervention 2: Given for fever control 10 mg/kg	intervention 1: Acetaminophen intervention 2: Ibuprofen	1	Hershey \| Pennsylvania \| United States \| -76.65025 \| 40.28592	60	0	0	0	NCT00267293	1COMPLETED	2009-06-01	2006-01-01	Penn State University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 5 ]	37	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	0ALL	true	The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients who have had a heart attack.	Aspirin reduces risks of heart attacks, strokes, and deaths from cardiovascular causes in patients who have survived a prior event as well as during an acute heart attack. Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability, or stickiness, and this is the mechanism whereby aspirin p...	Cardiovascular Diseases Atherosclerosis Myocardial Infarction	Cardiovascular diseases Aspirin Atherosclerosis Myocardial Infarction	null	5	arm 1: 81 mg Aspirin arm 2: 162 mg Aspirin arm 3: 325 mg Aspirin arm 4: 650 mg Aspirin arm 5: 1300 mg Aspirin	[ 1, 1, 1, 1, 1 ]	1	[ 0 ]	intervention 1: Dosage	intervention 1: Aspirin	2	Atlantis \| Florida \| United States \| -80.10088 \| 26.5909 Tamarac \| Florida \| United States \| -80.24977 \| 26.21286	37	0	0	0	NCT00272337	1COMPLETED	2009-06-01	2006-10-01	Florida Atlantic University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	62	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).	null	Kidney Neoplasms Carcinoma, Renal Cell		null	1	arm 1: AG-013736 single agent in continuous dosing until disease progression or unacceptable toxicity	[ 0 ]	1	[ 0 ]	intervention 1: AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles.	intervention 1: AG-013736 (axitinib)	5	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 The Bronx \| New York \| United States \| -73.86641 \| 40.84985 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Madison \| Wisconsin \| United States \| -89.40123 \| 43.07305	62	0	0	0	NCT00282048	1COMPLETED	2009-06-01	2006-03-01	Pfizer	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	237	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	null	The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.	null	Hyperlipidemia	Hyperlipidemia Proteinuria Diabetes Mellitus	null	0	null	null	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: Rosuvastatin intervention 2: Atorvastatin	107	Avondale \| Arizona \| United States \| -112.3496 \| 33.4356 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Pasadena \| California \| United States \| -118.14452 \| 34.14778 Riverside \| California \| United States \| -117.39616 \| 33.95335 Clearwater \| Florida \| United States \| -82.8001 \| 27.96585 Hollywood \| Florida \|...	236	0	0	0	NCT00296400	1COMPLETED	2009-06-01	2006-02-01	AstraZeneca	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	75	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to evaluate whether treatment with rituximab plus sargramostim will be more effective than rituximab alone.	On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. As of 29 August 2009, Genzyme assumed responsibility for the close out of the study. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc. The study was terminated early due t...	Lymphoma, Follicular	Sargramostim Leukine NHL	null	2	arm 1: None arm 2: None	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab intervention 2: Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks	intervention 1: Sargramostim (Leukine) intervention 2: Rituximab	22	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Montebello \| California \| United States \| -118.10535 \| 34.00946 Pleasant Hill \| California \| United States \| -122.0608 \| 37.94798 Gaines...	75	0	0	0	NCT00308087	6TERMINATED	2009-06-01	2006-05-01	Genzyme, a Sanofi Company	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3, 4 ]	13	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	Summary: Chloroquine is a medication that in laboratory settings has significant anti-HIV effects in HIV infected T-cells. Chloroquine has been used safely for over 60 years for malaria treatment and prevention, and it also has significant anti-inflammatory effects. No formal study of chloroquine has been performed in ...	Summary: A phase I randomized, double-blind, placebo controlled trial to investigate the efficacy of chloroquine to decrease T-cell activation and decrease viral load in early HIV. Scientific Rationale: Chloroquine has in vivo direct anti-HIV effects and an anti-inflammatory effect. These properties may be beneficia...	HIV Infections	HIV chloroquine disease progression inflammation treatment naive	null	2	arm 1: Chloroquine 205mg or 500mg orally once daily (Results pooled) arm 2: Placebo once daily for 8 weeks	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 250mg or 500mg PO (by mouth) QDay intervention 2: Placebo once daily for 8 weeks	intervention 1: chloroquine phosphate intervention 2: Placebo	1	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997	13	0	0	0	NCT00308620	6TERMINATED	2009-06-01	2006-03-01	University of Minnesota	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	115	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated central nervous system (CNS) metastases. A total of 115 patients enrolled in the study.	null	Non-Small Cell Lung Cancer Brain Neoplasms	Brain Cancer Brain Metastases Avastin NSCLC Lung Cancer PASSPORT	null	1	arm 1: None	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: 15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be \< 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity. intervention 2: Carboplatin, cisplatin, paclitaxel, docetaxel, gemcita...	intervention 1: bevacizumab intervention 2: First-Line Chemotherapy Agents intervention 3: Second-Line Chemotherapy Agents	0	null	106	0	0	0	NCT00312728	1COMPLETED	2009-06-01	2006-03-01	Genentech, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	7,287	RANDOMIZED	FACTORIAL	1PREVENTION	1SINGLE	false	0ALL	true	The purpose of the ACCORD-BONE Study is to investigate the effects of intensive glycemic control for type 2 diabetes (in ACCORD participants) on factors related to bone health, including, fractures, falls, and bone mineral density.	Recent studies have established that type 2 diabetes is a risk factor for fractures, particularly of the hip, shoulder and foot. Additionally, type 2 diabetes is associated with a 50-60% increase in the risk of falling. The higher risk of fracture associated with type 2 diabetes is an important health burden for these ...	Atherosclerosis Cardiovascular Diseases Hypercholesterolemia Hypertension Diabetes Mellitus Coronary Disease	Diabetes Mellitus Fracture Falls Height Loss	null	2	arm 1: intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%) arm 2: standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)	[ 1, 1 ]	1	[ 0 ]	intervention 1: type 2 diabetes treatments, per standard of care	intervention 1: hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents	5	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 Winston-Salem \| North Carolina \| United States \| -80.24422 \| 36.09986 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995 Memphis \| Tennessee \| United States \| -90.04898 \| 35.14953 Hamilton \| Ontario \| Canada \| -79.84963 \| 43.25011	0	0	0	0	NCT00324350	1COMPLETED	2009-06-01	2003-10-01	University of California, San Francisco	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 4 ]	30	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Parkinson's disease (PD) is the second most common neurodegenerative disease in the US, affecting nearly 1 million Americans. Up to 82% of community dwelling individuals with PD complain of sleep disturbances, typically sleep fragmentation. Despite the high prevalence of sleep problems and their impact on the life of t...	Introduction and Rationale Parkinson's disease (PD) is the second most common neurodegenerative disease in the US, affecting nearly 1 million Americans. Up to 82% of community dwelling individuals with PD complain of sleep disturbances, typically sleep fragmentation. This difficulty with sleep maintenance is accompanie...	Parkinson's Disease Insomnia	Parkinson's insomnia drug eszopiclone placebo	null	2	arm 1: eszopiclone. Those under 65yo received 3mg of eszoplicone ( or randomized to matching placebo)and those 65yo or older received 2mg of eszoplicone ( or randomized to matching placebo)taken each night at bedtime arm 2: Those randomly assigned to matching placebo, took their dose each night at bedtime	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: eszopiclone intervention 2: matching placebo administered at night	intervention 1: eszopiclone intervention 2: placebo	4	Suwanee \| Georgia \| United States \| -84.0713 \| 34.05149 Edison \| New Jersey \| United States \| -74.4121 \| 40.51872 Piscataway \| New Jersey \| United States \| -74.39904 \| 40.49927 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	30	0	0	0	NCT00324896	1COMPLETED	2009-06-01	2006-05-01	University of Medicine and Dentistry of New Jersey	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	75	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This is an investigator initiated dose finding study designed to determine the optimal dose of naloxone to prevent or minimize the most common side effects induced by opioids, namely itching, nausea, and vomiting. Male and female inpatients of the Children's Center of the Johns Hopkins Hospital, who are greater than 6 ...	In patients of all ages, opioids are the cornerstone of management of moderate to severe pain. Regardless of method of administration, all opioids produce unwanted side effects, including pruritus, nausea and vomiting, constipation, urinary retention, cognitive impairment, tolerance, dependence, and (rarely) respirator...	Pain Nausea Pruritus	morphine naloxone pediatrics adverse effects pain	null	1	arm 1: continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour	[ 0 ]	1	[ 0 ]	intervention 1: continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour	intervention 1: naloxone	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	59	0	0	0	NCT00330343	1COMPLETED	2009-06-01	2004-05-01	Johns Hopkins University	7OTHER	false	false	false	null	0	0	0	0	0	0
[ 3 ]	143	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the course of 12 months of active treatment.	null	Bladder, Neurogenic	tamsulosin pediatric neurogenic bladder	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: oral	intervention 1: tamsulosin hydrochloride	72	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218 Tampa \| Florida \| United States \| -82.45843 \| 27.94752 Springfield \| Illinois \| United States \| -89.64371 \| 39.80172 Indianapolis \| I...	377	0	0	0	NCT00340704	1COMPLETED	2009-06-01	2006-04-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 5 ]	145	RANDOMIZED	PARALLEL	2DIAGNOSTIC	3TRIPLE	false	0ALL	null	This is a clinical study of Xenetix 300 in Multislice Computed Tomography (MSCT) in pediatric indications.	null	Diagnostic Imaging	Multislice computed tomography (MSCT)indications	null	2	arm 1: The patient receive one injection of Xenetix 300 (300 mg of iodine/ml) arm 2: The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 300 mg of iodine/ml intervention 2: 270 mg of iodine/ml	intervention 1: Xenetix intervention 2: Visipaque	1	Rouen \| N/A \| France \| 1.09932 \| 49.44313	145	0	0	0	NCT00347022	1COMPLETED	2009-06-01	2006-05-01	Guerbet	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 4 ]	111	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in gastrointestinal (GI) complications in some patients. This study will 1) determine the proportion of patients with autoimmune diseases who are experiencing any GI complaints under MMF-based immunosuppressive treatment and 2) assess if a...	null	Autoimmune Disease	Autoimmune disease, mycophenolate, GI problems	null	1	arm 1: Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.	intervention 1: Enteric-coated Mycophenolate Sodium	1	Various Cities \| N/A \| Germany \| N/A \| N/A	111	0	0	0	NCT00351377	1COMPLETED	2009-06-01	2006-06-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	12	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to evaluate the ability of Phenoptin to control blood phenylalanine levels in subjects who have hyperphenylalaninemia due to a primary BH4 deficiency and to evaluate the safety of Phenoptin in this population. Some subjects were receiving non-registered formulations of BH4 at enrollment and...	Within 4 weeks of completing screening assessments to determine eligibility, subjects will be enrolled in the study. The study will be conducted in two parts. Part 1: After screening, all subjects will be followed for two weeks without modification of their baseline medical or dietary care. Part 2: Beginning at Week ...	Tetrahydrobiopterin Deficiencies Hyperphenylalaninemia, Non-Phenylketonuric		null	1	arm 1: 5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes invo...	[ 0 ]	1	[ 0 ]	intervention 1: 5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels	intervention 1: Phenoptin	10	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 New York \| New York \| United States \| -74.00597 \| 40.71427 Chapel Hill \| North Carolina \| United States \| -79.05584 \| 35.9132 Portland...	12	0	0	0	NCT00355264	1COMPLETED	2009-06-01	2006-08-01	BioMarin Pharmaceutical	4INDUSTRY	false	false	false	null	0	0	0	0	0	0
[ 3 ]	29	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.	Idiopathic pulmonary fibrosis (IPF) is recognized as a predominantly noninflammatory paradigm of lung fibrosis, characterized by heterogeneous myofibroblast proliferation (usual interstitial pneumonia \[UIP\]) and a poor clinical prognosis. To date no therapies have been demonstrated in well-designed, randomized, contr...	Alveolitis, Fibrosing Fibrosis, Pulmonary Hypertension, Pulmonary	alveolitis, fibrosing exercise, aerobic fibrosis, pulmonary hypertension, pulmonary	null	2	arm 1: Sildenafil 20 mg tid orally arm 2: Identical Placebo 20 mg tid orally	[ 0, 2 ]	1	[ 0 ]	intervention 1: Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.	intervention 1: sildenafil	1	Miami \| Florida \| United States \| -80.19366 \| 25.77427	29	0	0	0	NCT00359736	1COMPLETED	2009-06-01	2006-07-01	VA Office of Research and Development	1FED	false	false	false	null	0	0	0	0	0	0
[ 4 ]	330	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]).	null	Autistic Disorder Behavioral Symptoms	Serious behavioral problems in children and adolescents with AD behavioral problems	null	3	arm 1: De novo participants (those who did not participate in protocol (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, re...	[ 0, 0, 0 ]	1	[ 0 ]	intervention 1: Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks	intervention 1: Aripiprazole	55	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Dothan \| Alabama \| United States \| -85.39049 \| 31.22323 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tuscon \| Arizona \| United States \| N/A \| N/A Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Rolling Hills Estate \| California \| U...	330	0	0	0	NCT00365859	1COMPLETED	2009-06-01	2006-09-01	Otsuka Pharmaceutical Development & Commercialization, Inc.	4INDUSTRY	false	false	false	null	0	0	0	0	0	-0
[ 5 ]	12	RANDOMIZED	CROSSOVER	0TREATMENT	3TRIPLE	false	0ALL	true	The goal of this study is to confirm that levetiracetam has a better tic-suppressing profile than that of the widely used tic-suppressing medication, clonidine. More specifically, the investigators hypothesize that in a 15 week placebo run-in, double-blind, medication cross-over trial; levetiracetam will be more effect...	This is a randomized, double-blind, 15 week (two treatment phase), 1 week run-in, cross-over study, in which the same patient receives 6 weeks of treatment with levetiracetam and a 6 week treatment course with clonidine, separated by a two week medication wash-out. The investigators plan to enroll twenty patients betwe...	Tic Disorders Tourette Syndrome	Tics Tourette syndrome levetiracetam clonidine	null	2	arm 1: Levetiracetam (Keppra) is used in one phase of this cross-over study. The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic...	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proc...	intervention 1: Levetiracetam intervention 2: Clonidine	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	20	0	0	0	NCT00370838	1COMPLETED	2009-06-01	2007-02-01	Harvey S. Singer	7OTHER	false	false	false	null	0	0	0	0	0	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.